Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Alimentary Pharmacology & Therapeutics · 2025-02 · 61 (3) · 433-443
DOI: 10.1111/apt.18451 ↗At a glance
Metaanalyse in Alimentary Pharmacology & Therapeutics, published online on 2024-12-19. Written by Soroor Owrangi and 8 co-authors. Institution: Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA. Major MEDLINE topics: Liver Cirrhosis, Global Health. Cited 53 times so far (Crossref); 51 references.
Abstract (original language)
Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is responsible for a significant global health burden. Despite this burden, the prevalence and mortality of MASLD‐related cirrhosis remain inadequately defined, hindering effective public health strategies. This study aimed to estimate the global prevalence and mortality associated with MASLD‐related cirrhosis.
Methods
A systematic search of PubMed, Ovid MEDLINE, EMBASE, Web of Science and SCOPUS was conducted using keywords related to MASLD and cirrhosis from inception of each database used through June 2024. COVIDENCE was used for abstract and manuscript review. MASLD populations were categorised into ‘general practice setting’ and ‘high risk setting’, which indicated studies from inpatient setting or those referred for liver biopsy for an indication (elevated liver enzymes). Our data extraction and quality assessment followed PRISMA guidelines. A random‐effects model was utilised for meta‐analysis.
Results
From 7924 identified articles, 35 studies comprising 513,742 patients with MASLD met the inclusion criteria. The pooled global prevalence of cirrhosis among MASLD patients was 3.26% (95% CI: 2.47%–4.31%) in general practice settings (4 studies) and 14.51% (95% CI: 11.22%–18.57%) among those in inpatient settings or referred for liver biopsy (31 studies). Regionally, higher prevalence rates in high‐risk settings were observed in North America and Australia (18.38%; 95% CI: 9.06%–33.75%), followed by Europe (10.16%; 95% CI: 5.71%–17.44%) and Asia (9.12%; 95% CI: 6.11%–13.40%) ( p = 0.007). Notably, ICD‐based diagnoses indicated a significantly higher prevalence of cirrhosis (27.43%) compared to those diagnosed by liver biopsy (13.24%; p < 0.001). The pooled all‐cause mortality rate for MASLD‐cirrhosis patients was estimated at 7.91 per 100 person‐years (95% CI: 4.44–13.71) (9 studies).
Conclusions
This meta‐analysis underscores the substantial prevalence of cirrhosis among MASLD patients and highlights significant geographic and demographic variability, calling for improved screening and management strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
- The Global NASH Council, Washington, DC, USA.
- Center for Outcomes Research in Liver Disease, Washington, DC, USA.
ORCID profiles: Soroor Owrangi, James M Paik, Pegah Golabi, Linda Henry, Zobair M Younossi
Cite
APA
Owrangi, S., Paik, J. M., Golabi, P., de Avila, L., Hashida, R., Nader, A., Paik, A., Henry, L., & Younossi, Z. M. (2025). Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics, 61(3), 433-443. https://doi.org/10.1111/apt.18451
Vancouver
Owrangi S, Paik JM, Golabi P, de Avila L, Hashida R, Nader A, et al. Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. 2025;61(3):433-443. doi:10.1111/apt.18451
BibTeX
@article{Owrangi2025,
author = {Owrangi, Soroor and Paik, James M and Golabi, Pegah and de Avila, Leyla and Hashida, Ryuki and Nader, Ariana and Paik, Annette and Henry, Linda and Younossi, Zobair M},
title = {Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {61},
number = {3},
pages = {433--443},
doi = {10.1111/apt.18451}
}
EUVIMED